Key result
ASA plus dipyridamole inhibits platelet aggregation and increases bleeding time but fails to reduce consumption.
Why the study?
Does combined treatment with acetylsalicylic acid and dipyridamole improve platelet consumption and aggregation in patients with peripheral atherosclerotic disease?
RCT (n=9)
Double-blind
Randomized cross-over
Does combined treatment with acetylsalicylic acid and dipyridamole improve platelet consumption and aggregation in patients with peripheral atherosclerotic disease?
In patients with peripheral atherosclerotic disease, combined acetylsalicylic acid and dipyridamole inhibits platelet aggregation but fails to reduce platelet consumption.
ASA plus dipyridamole inhibits aggregation without reducing consumption in PAD; challenges presumed benefit and leaves open targeted alternatives.
The effect of combined treatment with acetylsalicylic acid and dipyridamole on platelet consumption and aggregation was studied in 9 patients with peripheral atherosclerotic disease. The trial was carried out as a randomized double‐blind, cross‐over study. All patients had increased consumption of blood platelets. The treatment produced a marked inhibition of platelet aggregation, increased the bleeding time, but did not reduce the platelet consumption.
No takes yet. Share an insight, caveat, or question.
Abrahamsen et al. (1974) conducted an RCT in Peripheral atherosclerotic disease (Atherosclerosis Obliterans) (n=9). Acetylsalicylic acid and dipyridamole was evaluated on Platelet consumption and aggregation. Combined treatment with acetylsalicylic acid and dipyridamole markedly inhibited platelet aggregation and increased bleeding time, but did not reduce platelet consumption.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: